Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 5;9:9776. doi: 10.1038/s41598-019-46170-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of ibrutinib on prostate cancer cell proliferation. (A) Ibrutinib inactivates PTK6 activity in vitro (as indicated in red). (B) RWPE-2, PC3, DU145, MDA-PCa-2b, and LNCaP cells were treated with increasing concentrations of ibrutinib for 48 h, and then cell proliferation was measured by MTT assay. *P < 0.05, **P < 0.005, ***P < 0.0005 compared with vehicle-treated cells. (C) RWPE-2, PC3, DU145, MDA-PCa-2b, and LNCaP cells were transfected with NC or miR-214 mimic for 24 h and then treated with increasing concentrations of ibrutinib for an additional 24 h. Cell survival was measured by MTT assay. *P < 0.05, **P < 0.005, ***P < 0.0005 compared with NC/miR-214-transfected and ibrutinib-treated cells. One-way ANOVA and two-way ANOVA, followed by Tukey’s multiple comparisons test were used to determine statistical significance. Results are representative of three independent experiments.